PCUR-101 + dutasteride

PCUR-101 + dutasteride is a combination of two drugs evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). PCUR-101 is an orally bioavailable small molecule derivative of plumbagin that inhibits several signaling pathways, including STAT3 (signal transducer and activator of transcription 3), protein kinase C epsilon, and proto-oncogene protein c-akt. Dutasteride is a 5α-reductase inhibitor used to suppress the conversion of testosterone to dihydrotestosterone (DHT), thereby reducing androgen-mediated signaling. The combination was tested in a clinical phase I setting to assess safety, maximum tolerated dose, pharmacokinetics, and preliminary efficacy in men with mCRPC who were already on androgen deprivation therapy. Clinical trials suggested that the combination was generally well tolerated, but trials were terminated at phase I due to factors such as insufficient enrollment and reformulation needs[1][2][3][4][5][7].

Other names

PCUR-101 + dutasteride